NCT05012397: Milademetan in Advanced/Metastatic Solid Tumors

NCT05012397
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated brain metastases; Patients with tumors that express TP53 & MDM2 gene amplification
https://ClinicalTrials.gov/show/NCT05012397

Comments are closed.

Up ↑